Avid Bioservices Inc (CDMO)

[Protector]

Carboat, of course not. And it is easy to prove.

Opdivo against Docetaxel alone ran on the same population of the SUNRISE Docetaxel alone for the First Look-in patients (US) and in the same overlapping years.

Docetaxel in that Opdivo performed LESS that Herbst et all 2010 (MOS 9.9) and the more recent maximum EVER 10.4 months MOS.

So what is wrong here is that UNDER YOUR statement Docetaxel performs less good if OTHER patience receive Opdivo and better if OTHER patients receive Bavituximab. So actually Opdivo could be a VERY BAD drug for patients because it has been compared to an under performing control arm (in its advantage). With Bavi it is the other way around (in its disadvantage).

CANNOT have had ANYTHING to do with your standards of care. Much more with the OPTIONS that patients have now since Opdivo is approved. They can get a 3rd line treatment in I-O and extend their life once that under Docetaxel alone their tumour progresses again.

This was identified as a risk by many. Both a healthier control and Opdivo as new SOC. All shot down as alarmist or impossible etc.

No it was not, it was AFTER the facts but not up-front. BTW up-front it was said that SUNRISE would not get any patients BECAUSE of Opdivo in the beginning.